EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Anti-Amyloid Therapy, AD, and ARIA: Untangling the Role of CAA

Mo-Kyung Sin iD, Edward Zamrini, Ali Ahmed iD, Kwangsik Nho, Ihab Hajjar

Journal of Clinical Medicine · 27.10.2023 · 12 (21) · 6792

DOI: 10.3390/jcm12216792 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 27.10.2023. Verfasst von Mo-Kyung Sin und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Nursing, Seattle University, Seattle, WA 98122, USA. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIH HHS, National Institute on Aging of the National Institute of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti-amyloid therapies (AATs), such as anti-amyloid monoclonal antibodies, are emerging treatments for people with early Alzheimer’s disease (AD). AATs target amyloid β plaques in the brain. Amyloid-related imaging abnormalities (ARIA), abnormal signals seen on magnetic resonance imaging (MRI) of the brain in patients with AD, may occur spontaneously but occur more frequently as side effects of AATs. Cerebral amyloid angiopathy (CAA) is a major risk factor for ARIA. Amyloid β plays a key role in the pathogenesis of AD and of CAA. Amyloid β accumulation in the brain parenchyma as plaques is a pathological hallmark of AD, whereas amyloid β accumulation in cerebral vessels leads to CAA. A better understanding of the pathophysiology of ARIA is necessary for early detection of those at highest risk. This could lead to improved risk stratification and the ultimate reduction of symptomatic ARIA. Histopathological confirmation of CAA by brain biopsy or autopsy is the gold standard but is not clinically feasible. MRI is an available in vivo tool for detecting CAA. Cerebrospinal fluid amyloid β level testing and amyloid PET imaging are available but do not offer specificity for CAA vs amyloid plaques in AD. Thus, developing and testing biomarkers as reliable and sensitive screening tools for the presence and severity of CAA is a priority to minimize ARIA complications.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer’s diseaseCSFamyloid βanti-amyloid therapycerebral amyloid angiopathyplasma

Autor:innen und Institutionen

  • College of Nursing, Seattle University, Seattle, WA 98122, USA.
  • Irvine Clinical Research, Irvine, CA 92614, USA.
  • VA Medical Center, Washington, DC 20242, USA.
  • School of Medicine, Indianna University, Indianapolis, IN 46202, USA.
  • School of Medicine, University of Texas Southwestern, Dallas, TX 75390, USA.

ORCID-Profile: Mo-Kyung Sin, Ali Ahmed

Förderung

  • NIA NIH HHS
  • NIH HHS
  • National Institute on Aging of the National Institute of Health

Zitieren

APA

Sin, M. K., Zamrini, E., Ahmed, A., Nho, K., & Hajjar, I. (2023). Anti-Amyloid Therapy, AD, and ARIA: Untangling the Role of CAA. Journal of Clinical Medicine, 12(21), 6792. https://doi.org/10.3390/jcm12216792

Vancouver

Sin MK, Zamrini E, Ahmed A, Nho K, Hajjar I. Anti-Amyloid Therapy, AD, and ARIA: Untangling the Role of CAA. Journal of Clinical Medicine. 2023;12(21):6792. doi:10.3390/jcm12216792

BibTeX
@article{Sin2023,
  author = {Sin, Mo-Kyung and Zamrini, Edward and Ahmed, Ali and Nho, Kwangsik and Hajjar, Ihab},
  title = {Anti-Amyloid Therapy, AD, and ARIA: Untangling the Role of CAA},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {21},
  pages = {6792},
  doi = {10.3390/jcm12216792}
}
Kostenlos starten →